HK Stock Market Move | 3SBIO (01530) rose more than 4%, gaining commercialization rights for multiple indications of the HER2 ADC drug DB-1303 developed by Immutep Biopharma.

14:10 16/01/2025

Sanbio (01530) rose more than 4%, as of the time of writing, it increased by 4.01%, reporting HKD 5.96, with a turnover of HKD 47.4687 million.

3SBIO (01530) rose over 4%, at the time of release, it was up by 4.01% at 5.96 Hong Kong dollars, with a transaction value of 47.4687 million Hong Kong dollars. On the news front, recently, 3SBIO's subsidiary Shenyang 3SBIO Co., Ltd. (referred to as 3SBIO) and IME Bio-Tech (Shanghai) Co., Ltd. (referred to as IME Bio-Tech) jointly announced that they have signed a cooperation agreement on the HER2 ADC drug DB-1303. According to the agreement, 3SBIO will obtain the commercialization rights of IME Bio-Tech's HER2 ADC drug DB-1303 for multiple indications in Mainland China, Hong Kong, and Macau. IME Bio-Tech will receive an initial payment as well as corresponding research and development and sales milestone payments. At the same time, IME Bio-Tech will continue to be responsible for clinical development and registration of related indications in the cooperation area.

Open Source Securities: Changes to this round of spring excitement after 8 consecutive gains

Huajin Securities: The spring market in January next year may continue, and technology is leading in some cyclical industries such as CKH HOLDINGS.

New stock prospects | 90% of revenue comes from the United States, how long can Universal Horticulture continue to benefit from going global?

Open Source Securities: Changes to this round of spring excitement after 8 consecutive gains

Huajin Securities: The spring market in January next year may continue, and technology is leading in some cyclical industries such as CKH HOLDINGS.

New stock prospects | 90% of revenue comes from the United States, how long can Universal Horticulture continue to benefit from going global?